Photo taken from Manni Mohyuddin/X
Nov 28, 2023, 23:17
Manni Mohyuddin: Current trials must have observation/surveillance as control arm
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared a post by
Multiple Myeloma Hub, on Twitter, adding the following:
“The majority of clinicians recommend against routine treatment of smoldering myeloma- instead preferring active surveillance.
Future/current trials must have observation/surveillance as control arm as that is the preferred/current standard of care.”
Quoting Multiple Myeloma Hub:
“Clinician preferences on the treatment of smoldering multiple myeloma, check out our key points below!
What treatment would you recommend for smoldering multiple myeloma? HCPs, share your thoughts below!”
Source: Manni Mohyuddin/Twitter and Multiple Myeloma Hub/Twitter
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 13:14
Aug 8, 2025, 13:14
Aug 8, 2025, 13:11